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1406 The Journal of Thoracic and CardObjectives: The cyclooxygenase 2 enzyme has become a therapeutic target in cancer
treatment. Cyclooxygenase 2 blockade with selective inhibitors increases apoptosis
and decreases the metastatic potential of lung cancer cells. Some of the antitumor
effects of these inhibitors may occur through both cyclooxygenase 2-dependent and
independent pathways. Our goal was to investigate these pathways using celecoxib
(selective cyclooxygenase 2 inhibitor) and 2,5-dimethyl celecoxib, a structural
analog modified to eliminate cyclooxygenase 2 inhibitory activity, while potentially
maintaining antineoplastic properties.
Methods: 2,5-Dimethyl celecoxib was synthesized in the Department of Chemistry
at the University of Southern California. With the use of non–small cell lung cancer
cells (A549), prostaglandin E2 production was quantified by enzyme-linked immu-
nosorbent assay to assess cyclooxygenase 2 activity. Cell proliferation was assessed
by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt assay. Cell migration was performed using transwell inserts
that were matrigel coated for invasion experiments. Gelatin zymography was used
to assess matrix-metalloproteinase activity.
Results: 2,5-Dimethyl celecoxib did not inhibit interleukin-1–stimulated prosta-
glandin E2 production, whereas celecoxib did even at low doses. Both celecoxib and
2,5-dimethyl celecoxib decreased tumor cell viability and proliferation with IC50 for
celecoxib and 2,5-dimethyl celecoxib of 73 and 53 mol/L, respectively. Both drugs
were also potent inducers of apoptosis, and both inhibited tumor cell migration and
invasion. This was associated with down-regulation of matrix metalloproteinase
activity.
Conclusions: 2,5-Dimethyl celecoxib is a structural analog of celecoxib that lacks
cyclooxygenase 2 inhibitory activity but exhibits significant antineoplastic proper-
ties comparable to celecoxib. This suggests that the antineoplastic activities of
celecoxib are, at least in part, cyclooxygenase independent and that therapeutic
strategies can be developed without the side effects of global cyclooxygenase 2
blockade.
T he cyclooxygenase 2 (COX-2) enzyme is up-regulated in most non–smallcell lung cancer (NSCLC) and appears to be involved in apoptosis, angio-genesis, and metastasis.1-4 Inhibition of the enzyme by COX-2–specific
blockade has resulted in retardation of tumor growth in heterotopic and orthotopic
lung cancer animal models, and a decrease in the progression to mediastinal
metastases.5,6 Most of the antineoplastic effects of the COX-2 inhibitors have been
observed with the drug celecoxib, and indeed this compound appears to have
superior anticancer effects than the other two available selective COX-2 inhibitors,
rofecoxib and valdecoxib.7-10 Although many of the antineoplastic effects of cele-
coxib may be related to down-regulation of prostaglandin E2 (PGE2) and other
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independent of COX-2 activity.9,11-14
Epidemiologic reports and early clinical trials suggest
that celecoxib has both chemotherapeutic and chemopre-
ventative potential.15-19 The fact that the drug has been
implicated as having antimetastatic activity is of particular
importance in the treatment of early lung cancer, because
distant disease will ultimately recur in up to 40% of patients
undergoing “curative” surgical resection. In view of the fact
that celecoxib is a relatively safe medication with remark-
ably few renal or gastrointestinal side effects, it may have a
potential role as an adjuvant strategy in treating patients
with lung cancer. However, the recent reports of unexpected
cardiovascular side effects resulting from long-term (and
high-dose) COX-2 inhibition challenge us to investigate
further which antineoplastic effects are indeed COX-2 de-
pendent and which may be the result of COX-2–indepen-
dent mechanisms.20 The goal of this study was to examine
the effects of celecoxib and a structural analog, namely,
2,5-dimethyl celecoxib (DMC), which lacks COX activity,
on cellular proliferation, apoptosis, migration, and invasion
in NSCLC. DMC has been studied in prostate cancer and
lymphoma and has been shown to be a potent inducer of
apoptosis in vitro as well as an inhibitor of tumor xenografts
in vivo.21,22 However, the effects of this compound on lung
cancer cells, and its potential for affecting metastatic be-
havior, are not known.
Study Design
The goals of this study were to examine the effects of celecoxib
and DMC on tumor cell behavior in vitro. With the use of NSCLC
cells (A549), we aimed to establish the effects of both compounds
on relative COX-2 inhibition by using an enzyme-linked immu-
noassay test for PGE2 production as a measure of COX-2 activity.
We subsequently examined the effects on cell viability, prolifera-
tion, and apoptosis using 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
Abbreviations and Acronyms
COX-2  cyclooxygenase 2
DMC  2,5-dimethyl celecoxib
FBS  fetal bovine serum






NSCLC  non–small cell lung cancer
PBS  phosphate-buffered saline
PGE2  prostaglandin E2
RPMI  Roswell Park Memorial Institute(MTS) assays and annexin V fluorescein isothiocyanate (FITC)
The Journal of Thoracicfluorescence-activated cell sorter analysis. Finally, we studied tu-
mor cell migration and invasion as a means to assess effects on
tumor metastatic potential and used gelatin zymography to assess
matrix metalloproteinase (MMP) activity to understand the mech-
anisms responsible for the above effects.
Laboratory Procedures
Cells and Reagents
A549 human lung adenocarcinoma cells were purchased from
American Type Culture Collection (Manassas, Va). Cells were
cultured in Roswell Park Memorial Institute (RPMI) 1640 supple-
mented with 5% fetal bovine serum (GIBCO, Carlsbad, Calif), 2
mmol/L glutamine, 100 U/mL penicillin, and 100 g/mL strepto-
mycin at 37°C in a 5% CO2 humidified incubator. Before exper-
iments, cells were washed with phosphate-buffered saline (PBS)
and trypsinized. Cell viability of more than 95% was confirmed by
trypan blue staining.
DMC is a structural analog of celecoxib, in which the 5-aryl
moiety has been modified to replace the 4-methylphenyl with
2,5-dimethylphenyl, resulting in 4-[5-(2,5-dimethylphenyl)-3-(tri-
fluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (Figure 1).
This compound was synthesized in our laboratories after a proce-
dure analogous to the synthesis of celecoxib.22,23 The synthesized
compounds were characterized by 1H- and 13C-NMR spectros-
copy. Both agents were dissolved in dimethyl sulfoxide and added
to cells in medium at various concentrations. The final concentra-
tion of dimethyl sulfoxide was kept at 1% after addition to
medium.
Prostaglandin E2 Immunoassay
For determination of PGE2 activity, A549 cells at 5 103 cells per
well were seeded onto 96-well plates in 100 L RPMI 1640
medium containing 5% fetal bovine serum (FBS). After attach-
ment overnight, cells were washed with PBS and treated with
medium alone, vehicle, celecoxib, or DMC at various concentra-
tions. Interleukin (IL) 1 was added to stimulate PGE2 production
over baseline to mimic increased COX-2 activity as is observed in
in vivo tumors.1 Cell supernatant was collected and immediately
Figure 1. Chemical structures of celecoxib and 2,5-dimethyl cele-
coxib (DMC). The 5-aryl moiety has been modified to replace
the 4-methylphenyl with 2,5-dimethylphenyl, resulting in 4-[5-
(2,5-dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzen-
esulfonamide.kept at70°C. PGE2 concentration was detected by PGE2 Biotrak
and Cardiovascular Surgery ● Volume 130, Number 5 1407
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away, NJ) according to the manufacturer’s instructions.
Viability and Proliferation
Cells were seeded onto 96-well plates as described. Celecoxib or
DMC at 0, 10, 20, 50, 75, and 100 mol/L concentrations were
added to cell culture media containing 5% FBS. Cell viability was
assessed at 24 hours post-treatment; 48- and 72-hour time points
were used to assess proliferation effects. Both viability and pro-
liferation studies were performed with MTS assay. Twenty micro-
liters of CellTiter 96 AQueous One Solution Reagent (MTS)
(Promega, Madison, Wis) was added to cells and incubated for 90
minutes at room temperature. Viable cells convert MTS to an
aqueous formazan product, which was measured by absorbance at
490 nm. All treatments were performed in triplicate. The IC50 was
calculated from the 24-hour viability data based on the optical
density reading.
Apoptosis
Induction of apoptosis was assessed by phosphatidylserine exter-
nalization using an Annexin V-FITC Apoptosis Detection Kit
(BioVision, Mountain View, Calif) according to the manufactur-
er’s instructions. A549 cells at 5  105 per well were seeded onto
a 12-well plate in 1 mL RPMI 1640 medium containing 5% FBS.
Cells were allowed to attach overnight and treated with various
doses of celecoxib or DMC for 24 hours. Cells were washed with
PBS before and after harvesting, then resuspended in 0.5 mL
binding buffer, and incubated with 5 L of FITC-conjugated
Annexin V (BioVision) for 5 minutes at room temperature. Apo-
ptotic cells were quantified with Annexin V-FITC binding per-
Figure 2. PGE2 enzyme-linked immunosorbent assay. Cells were
treated with IL1 at 1 ng/mL and celecoxib or DMC at 10 or 50
mol/L. Supernatant was collected and PGE2 levels were quan-
titated by enzyme-linked immunosorbent assay. Plotted values
represent log PGE2 (pg/mL) mean  SD. PGE2, Prostaglandin E2;
IL, interleukin; Cel, celecoxib; DMC, 2,5-dimethyl celecoxib.centage by fluorescence-activated cell sorter analysis.
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Costar Transwell inserts (Costar, Corning, NY) containing 8-m
pores were used in migration experiments, and BD Biocoat Ma-
trigel Invasion Chambers (Beckton Dickinson, Bedford, Mass)
were used for invasion experiments. Cells were placed in serum-
free media for 24 hours before experiments. After this, they were
plated at a concentration of 2.5  104 cells per insert. Given the
difference in the IC50, as determined by viability studies, we chose
to examine the effects on cell migration and invasion using drug
concentrations appropriate for each compound. Celecoxib was
added at 10, 25, and 50 mol/L concentrations, whereas DMC was
added at 5, 10, and 25 mol/L concentrations to the cell suspen-
sions. Serum containing 10% FBS was used as a chemoattractant
in the bottom wells. Treatment conditions were carried out in
triplicate. Cells were allowed to incubate for 24 and 48 hours for
migration and invasion experiments, respectively. At the end of the
experiment, cells were manually removed from the top of the
membrane. The migrated or invaded cells adherent to the under-
surface of the membrane were then fixed and stained with hema-
toxylin and counted under light microscopy at 400 in 8 random
fields. Percent migration or invasion was expressed as the percent-
age of migrated or invaded treated cells compared with control.
Gelatin Zymography
Gelatin zymography was performed to assess relative matrix met-
alloproteinase activity. Cells were plated onto 6-well plates at a
concentration of 106 cells per well. After the addition of celecoxib
or DMC, cells were allowed to incubate for 48 hours and the
supernatant was collected. Supernatants were concentrated using
Millipore Amicon Ultra-4 centrifuge tubes (Fisher Scientific, Pitts-
burgh, Pa), and protein quantification was performed with a stan-
dard protein assay (Bio-Rad, Hercules, Calif).
Protein was loaded at 20 g per lane with Tris-Glycine SDS
Sample Buffer onto Novex 10% Zymogram Ready Gels (Invitro-
gen, Carlsbad, Calif). Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis was performed at 125 V for 90 minutes. Gels then
underwent serial washes in Zymogram Renaturing Buffer and
Zymogram Developing Buffer (Invitrogen) for 30 minutes each at
room temperature, followed by incubation overnight at 37°C.
Areas of gelatinase activity were visualized as lytic bands after
staining with Coomassie blue and imaged using Flourochem 8900
(Alpha Innotech, San Leandro, Calif), AlphaEase imaging soft-
ware 5.0 (Alpha Innotech), and Adobe Photoshop 6.0 (Adobe
Systems Inc, San Jose, Calif).
Statistical Analysis
Derivation of IC50 was based on linear regression for optical
density reading and dose. Linear regression analysis was used to
determine the significance of the change of migration or invasion
activities with different dose levels. Experiments were performed
in triplicate, and the data are expressed as mean  standard
deviation unless otherwise indicated.
Results
Effect on COX-2 Inhibitory Activity In Vitro
Cells treated with IL1 demonstrated significant COX-2
activity as shown by high levels of PGE2 production. Cele-
ember 2005
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as low as 10 mol/L with a return of levels to baseline. In
contrast, treatment with DMC showed no inhibition of
IL1-induced PGE2 production consistent with minimal
COX-2 inhibitory activity (Figure 2).
Effects on Cell Viability, Proliferation, and Apoptosis
The IC50 for DMC was 53 mol/L, whereas the IC50 for
celecoxib was 73 mol/L at 24 hours. Additional treatment
for 48 and 72 hours inhibited cell proliferation in a dose-
dependent manner (Figure 3). An increase in apoptosis was
also seen at doses near the IC50 for both drugs (Table 1).
DMC demonstrated greater potency for apoptosis induction
compared with the parent compound celecoxib.
Effects on Cell Migration and Invasion
The results of the migration and invasion experiments are
depicted in Figures 4 and 5. Cells demonstrated active
migration and invasion when treated with vehicle alone.
Treatment with DMC at 5, 10, and 25 mol/L resulted in
significantly decreased tumor cell migration of 61%
(10%), 51% (10%), and 0% (P  .0001), respectively.
Treatment with celecoxib resulted in migration inhibition of
27% (12%), 29% (5%), and 0% at concentrations of 10,
25, and 50 mol/L (P  .0005), respectively (Figure 6).
Cellular invasion through the matrigel barrier was also
inhibited by both drugs. DMC resulted in reduced tumor cell
invasion of 60% (15%), 34% (13%), and 0% (P 
.0001) at concentrations of 5, 10, and 25 mol/L, respec-
tively, whereas celecoxib reduced cell invasion demonstrat-
ing 85% (2%), 32% (9%), and 2% (3%) invasion at
concentrations of 10, 25, and 50 mol/L (P  .0001),
respectively (Figure 4).
Because cancer cell invasion and migration through the
extracellular matrix are known to be mediated by the pro-
duction and activation of MMPs, we examined the cell
culture supernatants for MMP-2 and MMP-9 activity by
Figure 3. Viability and proliferation. MTS assay was per
24, 48, and 72 hours. Twenty-four–hour data were used t
and 72-hour data reflect effects on cell proliferation. Datgelatin zymography. In the presence of either DMC or
The Journal of Thoraciccelecoxib, MMP activity was down-regulated. Specifically,
MMP-9, and to a lesser extent MMP-2, activity was inhib-
ited in a dose-dependent manner (Figure 5).
Discussion
NSCLC can be thought of as a systemic process from an
early stage despite imaging studies that may show localized
disease. Metastases will recur in many patients even after
curative surgical resection. This has prompted exploration
into the possible roles of adjuvant therapies even for early
stage disease, with some preliminary reports suggesting a
survival benefit to this approach.24,25 Given the many po-
tential antineoplastic effects of celecoxib including an effect
on the metastatic potential of NSCLC, this agent may have
a role as adjuvant therapy in the treatment of early stage
disease.26
The underlying mechanisms for many of the antineoplas-
tic effects of the COX-2 inhibitors, however, are still ill-
defined. It is thought that some effects may be the result of
COX-2 independent mechanisms that might therefore be
separated from the COX-2 inhibitory activity of this class of
d with cells treated with celecoxib (A) and DMC (B) for
rmine the IC50 by linear regression analysis. Forty-eight
expressed as mean  SD. OD, Optical density.
TABLE 1. Apoptosis as detected by phosphatidylserine ex-
ternalization using an annexin V-fluorescein isothiocya-




10 mol/L 11.10 17.67
25 mol/L 12.16 23.87
50 mol/L 14.09 38.15
75 mol/L 30.57 Not tested
DMC, 2,5-Dimethyl celecoxib; DMSO, dimethyl sulfoxide. Cells were treated
with various doses of celecoxib or DMC for 24 hours. The data shown
represent the percentage of apoptotic cells.forme
o dete
a aredrug. The evidence for COX-independent mechanisms is
and Cardiovascular Surgery ● Volume 130, Number 5 1409
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have found that COX-2 inhibitors affect apoptosis and via-
bility in these cell lines independent of the level of cellular
COX-2 expression.9,12 Song and colleagues8 showed in
prostate cancer cells that down-regulation of COX-2 expres-
sion by antisense COX-2 cDNA successfully blocked pros-
taglandin production, yet had little effect on cell viability.
Further, in studying other well-known COX-2 inhibitors
and structural analogs, no correlation could be found be-
tween the level of anti–COX-2 activity and apoptosis in-
duction. Although some analogs were potent inducers of
apoptosis, they lacked COX-2 inhibitory activity and vice
versa.22,27
Figure 4. Cellular invasion. A549 cells were treated wit
and placed onto transwell chambers containing 8-
incubation, migrated cells adherent to the undersurface
counted by light microscopy in 8 random fields. The
migrated cells compared with control. Data shown re
Figure 5. Gelatin zymography was performed by treating cells
with (A) celecoxib or (B) DMC at the indicated concentrations
and collecting the culture supernatant after 48 hours of incuba-
tion. MMP activity can be seen as lytic bands on a dark back-
ground after staining with Coomassie blue. DMSO, Dimethyl
sulfoxide; MMP, matrix metalloproteinase.
1410 The Journal of Thoracic and Cardiovascular Surgery ● NovLimited attempts have been made at pharmacologic ex-
ploitation of the antineoplastic properties of these com-
pounds to generate targeted therapies for cancer and thereby
mitigate some of the potential adverse effects. The goal of
this study was to investigate the antineoplastic properties of
the selective COX-2 inhibitor, celecoxib, and a structural
analog of this compound, namely, dimethyl-celecoxib, in
NSCLC.
We demonstrated that DMC lacked COX-2 activity by
having little effect on the production of PGE2 in stimulated
cells, whereas celecoxib inhibited the COX-2 enzyme even
at low doses. It is thought that the bulkier 2,5-dimethylphenyl
ring does not allow the drug to fit into the active site of
COX-2. Previous studies using celecoxib derivatives have
concluded that certain structural elements are vital to induc-
tion of apoptosis. These include increased polarity or bulk-
iness of the terminal phenyl ring, a heterocyclic system with
negative electrostatic potential, and benzenesulfonamide or
benzenecarboxamide moiety (Figure 1).8,27,28 Moreover,
the structural elements required for apoptosis were different
from those required for COX-2 inhibitory activity.27
We were able to demonstrate potent antineoplastic ef-
fects of DMC comparable to the parent compound celecoxib
in the NSCLC cell line A549 despite this lack of COX-2
activity. Both compounds inhibited cell viability and pro-
liferation, and promoted apoptosis. These results are con-
sistent with previous studies in prostate cancer and lym-
phoma cell lines using this compound.8,22,27 Both drugs are
thought to exhibit their antitumor effects through similar
alterations of activity of cellular kinases such as IKK,
ERK2, and Akt.8,10,13,27,29 Additional reports implicate
other cell-cycle regulator proteins including cyclin A and
B.7,22
We further demonstrated that DMC (as well as cele-
lecoxib (A) or DMC (B) as in the migration experiments
res coated with matrigel extracellular matrix. After
he membrane were then stained with hematoxylin and
entage of migration is defined as the percentage of
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effects are mediated, in part, by down-regulation of MMP
activity. The ability of a cancer cell to migrate and invade
through an extracellular matrix is an integral step in the
metastatic process. Previous studies in colorectal carcinoma
showed that treatment with selective and nonselective
COX-2 inhibitors resulted in decreased tumor cell migration
and invasion through down-regulation of MMP-2 and
MMP-9.30,31 We found that both celecoxib and DMC treat-
ment resulted in decreased MMP-9 activity; however, inhi-
bition of MMP-2 activity was more pronounced in cells
treated with celecoxib. This is consistent with studies that
showed that MMP-2 activity was more closely linked to
PGE2 production and therefore COX-2 activity.31-33 Thus
inhibiting this ability with either compound may play a role
in decreasing tumor metastasis in vivo and in preventing the
progression of disease in patients with early-stage lung
cancer.
The facts that DMC lacks COX-2 inhibitory activity and
that the concentration of celecoxib required for cell death
was several fold higher than the minimal concentration
required for COX-2 inhibition are further evidence that the
antitumor effects of celecoxib and DMC are not solely
related to COX-2 enzymatic activity. The effects that are
observed in vivo are, of course, likely more complex. Fur-
thermore, the cardiovascular side effects of the COX-2
inhibitors are hypothesized to be secondary to an imbalance
between prothrombotic and antithrombotic prostanoids
leading to a prothrombotic state in which there is relatively
more thromboxane produced by COX-1 and relatively less
prostacyclin produced by COX-2. Ideally, more in vitro
studies should be performed with selective COX-2 inhibi-
tors and analog compounds to specifically target these pro-
stanoids to investigate additional mechanisms for COX-2–
independent processes before expanding research into the
Figure 6. Cellular migration. A549 cells were treated w
and placed onto transwell chambers containing 8-m
undersurface of the membrane were then stained with
fields. The percentage of migration is defined as the
shown represent mean  SD. DMSO, Dimethyl sulfoxclinical arena.
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Discussion
Dr Mark J. Krasna (Baltimore, Md). Your article is very
interesting, and I enjoyed your presentation. Can you explain
what you think the possible mechanism of the apoptosis induc-
tion is? In other words, how does either celecoxib or DMC
induce apoptosis?
Dr Backhus. I would love to describe that for you in great
detail, but I don’t think that there is a real consensus as to what the
mechanism is. It is still being worked out right now. There are a
number of theories proposed. The ERK pathway, AKT pathway,
bcl-2, and many other pathways have implicated celecoxib in that
process.
Dr Krasna. And my other question is a specific question regard-
ing your comment. We all worried when we read your article that
there would be no future for this, but obviously there is if you use
DMC. Are there data to show the safety in terms of the side effects of
cardiac risk factors on DMC? Is that available yet clinically?
Dr Backhus. There are no human trials using DMC at this time.
There are scattered reports from various in vivo studies using different
cancer types. For instance, there was a study performed that shows
essentially the same effects that we see with celecoxib in prostate
cancer. They looked at serum levels and showed decreased tumor
metastases in this prostate cancer model. They also showed that DMC
has better bioavailability, resulting in higher serum levels than cele-
coxib. There is another group on our campus who are looking at
glioblastoma and lymphoma cell lines, and they have produced some
promising data as well. But again, this is just in mice.
Dr Robert C. Robbins (Stanford, Calif). What if you used cell
lines from bcl-2 knockouts or bcl-2 overexpressers and used these
drugs? This is sort of an unfair question, but just because we can’t
think of anything else good to ask you, what do you think would
happen?
Dr Backhus. I suspect that there would definitely still be some
benefit because of the other pathways implicated. We have also
looked at other NSCLC cell lines in addition to A-549, at least 2
others in our laboratory alone, and we see similar results regardless
of the level of COX-2 expression. The other group looking at
glioblastoma is using a number of cell lines that have minimal
COX-2 activity but also show this same effect.
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